Search

Initiatives in macular service provision

A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...

IN FOCUS - Prevention and treatment of blindness worldwide: the story of ‘VISION 2020: The Right to Sight’

The story of blindness and efforts to prevent and treat it cannot be told without going back to the earliest recorded history of blindness. Trachoma was described in ancient Egypt, cataract surgery in India about the fifth century BC and...

Beyond 2020 Episodes 01-03

Introduction Working in remote, Amazonian villages, the Andean Medical Mission (AMM) have made progress into eliminating avoidable blindness in this small corner of the globe and have produced a video series, Beyond 2020, to share what they’ve learned over 12...

Brain tumours in adults: the essentials for an ophthalmologist

The author provides a review of the common intracranial tumours in adults (other than pituitaries) which may present to an ophthalmologist. Primary malignant brain tumours comprise 3% of adult cancers but with an ageing population such tumours are becoming more...

Under pressure: a tool to aid the 
non-ophthalmic practitioner in the timely management of acute angle closure

Acute angle closure is a true ophthalmic emergency that mandates timely diagnosis and treatment. The priority in initial management is to lower the intraocular pressure in an expeditious matter using medical treatments. The risk of irreversible glaucomatous optic neuropathy is...

Usher syndrome: an overview

Usher syndrome is the most common hereditary condition that affects both vision and hearing. It is an autosomal recessive condition characterised by retinitis pigmentosa (RP) and bilateral sensorineural hearing loss [1,2]. Usher syndrome is the cause of approximately 10% of...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...